1. Psychopharmacologic Management of Serious Behavioral Disturbance in ASD
- Author
-
Kimberly A. Stigler
- Subjects
medicine.medical_specialty ,Disturbance (geology) ,Population ,Poison control ,Irritability ,Antimanic Agents ,Adrenergic alpha-2 Receptor Agonists ,medicine ,Humans ,education ,Psychiatry ,Clinical Trials as Topic ,education.field_of_study ,Risperidone ,Aggression ,medicine.disease ,Combined Modality Therapy ,Irritable Mood ,Psychiatry and Mental health ,Child Development Disorders, Pervasive ,Pediatrics, Perinatology and Child Health ,Autism ,Anticonvulsants ,Aripiprazole ,medicine.symptom ,Psychology ,Self-Injurious Behavior ,Antipsychotic Agents ,medicine.drug ,Clinical psychology - Abstract
Individuals diagnosed with autism spectrum disorders (ASD) often exhibit serious behavioral disturbance (irritability) including severe tantrums, aggression, and self-injury that requires pharmacologic management. Research focused on the treatment of severe irritability has primarily involved the atypical antipsychotics, including risperidone and aripiprazole. Anticonvulsants have also been investigated for targeting serious behavioral disturbance; however findings have been mixed. Advances in the pharmacotherapy of irritability in ASD continue to inform practice. Research is needed to develop safer and more effective drug treatments for serious behavioral disturbance in this population. Language: en
- Published
- 2014